HER2+ Lung Cancer at ESMO 2025

from Medical News Podcast · host PeerDirect Publishing

Drs. Yu and Herzberg discuss recent developments in HER2- and EGFR-targeted therapies for lung cancer, focusing on clinical trial results at ESMO 2025. Key highlights include promising response rates, toxicity profiles, and the potential for these targeted therapies to treat patients with specific genetic mutations, particularly those with CNS metastases.

Episode metadata supplied by the publisher feed · Published Dec 30, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

HER2+ Lung Cancer at ESMO 2025

0:00 13:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical News Podcast?

This episode is 13 minutes long.

When was this Medical News Podcast episode published?

This episode was published on December 30, 2025.

Can I download this Medical News Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!